Last updated: 2026-10-08 21:05:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Becton, Dickinson and Co. (BDX) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NYSE. The stock is currently priced at $182.69, with a market capitalization of $49.11B and a P/E ratio of 52.15. Over the past 52 weeks, its price has ranged from $140.11 to $213.08. This page covers its latest market performance, valuation, price trends and company information.
$49.11B | |
$179.76 | |
$287.32 | |
$34.10 | |
$180.16 | |
1.22M | |
1.79M | |
52.15 | |
$213.08 | |
$140.11 | |
2.39% | |
-- |
Becton, Dickinson and Co. (BDX) is trading at $181.13 in after-hours trading as of 2026-10-08 20:17:42, up 0.54% ($0.97) from the regular-session close of $180.16.
After-hours trading shows how investors are pricing BDX after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Becton, Dickinson and Co. (BDX) moved from $181.97 to $182.69, representing a gain of 0.40% ($0.72).
The stock traded between $175.71 and $187.45 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 1.73 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 58.4%
BDX is currently trading at $182.69, placing it 58.4% of the way from its 52-week low of $140.11 to its 52-week high of $213.08. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Following the separation of the life science segment, Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 72000 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Becton, Dickinson and Co. (BDX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.